Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 37

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 37
---
  that it was not an appropriate forum for such proceedings;  

  that, applying Australian conflict of laws rule, U. S. law (including U. S. securities laws) did not apply to the relationship between holders of our ordinary shares or ADSs and us or our direc...  

  that the U. S. securities laws were of a public or penal nature and should not be enforced by the Australian court.  

Holders of our ordinary shares
and ADSs may also have difficulties enforcing in courts outside the United States judgments that are obtained in the U. S. courts against
any of our directors and executive officers or us, including actions under the civil liability provisions of the U. S. securities laws.

As a foreign private issuer whose ADSs are
listed on the Nasdaq Capital Market, we may follow certain home country corporate governance practices instead of certain Nasdaq requirements.

As a foreign private issuer
whose ADSs are listed on the Nasdaq Capital Market, we are permitted to follow certain home country corporate governance practices instead
of certain requirements of The Nasdaq Marketplace Rules. For instance, we may follow home country practice in Australia with regard to
the composition of the board of directors and director nomination process. In addition, we may follow Australian law instead of the Nasdaq
Marketplace Rules that require that we obtain shareholder approval for certain dilutive events, such as for the establishment of equity-based
compensation plans, an issuance that will result in a change of control of the company, certain transactions other than a public offering
involving issuances of a 20% or more interest in the company and certain acquisitions of the shares or assets of another company. Accordingly,
our shareholders may not be afforded the same protection as provided under Nasdaq’s corporate governance rules that are applicable
to U. S. companies.

As a foreign private issuer, we are exempt
from a number of rules under the U. S. securities laws and are subject to lower disclosure requirements under U. S. law compared to a U. S.
company.

As a “foreign private
issuer” (as defined in the SEC’s rules), we are not subject to all the disclosure requirements applicable to U. S. public companies.
For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements
related to the solicitation of proxies under the Exchange Act. In addition, our senior management and directors are exempt from the reporting
and “short-swing” profit recovery provisions of Section